Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study - Takeaways - MDSpire

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

  • By

  • Xin Wan

  • Dechuan Liu

  • Haotian Wang

  • Wei Guo

  • Xingtong Wang

  • Yangzhi Zhao

  • Ou Bai

  • June 18, 2026

  • 0 min

Share

  • 1

    Obinutuzumab-based chemotherapy significantly improved complete response rates compared to rituximab in patients with high-tumor burden lymphoma.

  • 2

    The obinutuzumab group demonstrated superior 3-year progression-free survival and overall survival rates compared to the rituximab group.

  • 3

    The incidence of disease progression within 24 months was lower in patients treated with obinutuzumab compared to those treated with rituximab.

  • 4

    Rituximab-based treatment was identified as an independent risk factor for inferior overall survival in multivariable analysis.

  • 5

    Safety profiles were similar between obinutuzumab and rituximab groups, with no significant differences in adverse event rates.

Original Source(s)

Obinutuzumab versus rituximab-based chemotherapy in high-tumor burden indolent B-cell lymphoma: a real-world comparative study

  • by Xin Wan, Dechuan Liu, Haotian Wang, Wei Guo, Xingtong Wang, Yangzhi Zhao, Ou Bai

  • June 18, 2026

Related Content

Early detection of multiple cancers: the era of methylation-based liquid biopsy

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report

Editorial: Type 2 inflammatory skin diseases: novel therapies and clinical insights